The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein acidic and rich in cysteine (... full article
BACKGROUND: Inhibition of the hedgehog signaling pathway (HHSP) for the treatment of locally advanced basal cell carcinoma (BCC) and metastatic BCC (mBCC) has produced promising results. Typically, mBCC is not taken into consideration during the workup of a patient with multifocal metastatic disease who has a history of BCC. The objective of... full article
The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with advanced BCC participating in a phase I dose-escalation... full article
Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).
Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are... full article
Dr. Ron Korn involved in study published to PubMed.
To evaluate the feasibility of constructing radiogenomic-based... full article
Imaging to Cure Cancer: Valuable Contribution of Radiology for Clinical Trial Success
Written by Dr. Ron Korn, Founder, Chairman and Chief Medical Officer at Imaging Endpoints
“I keep dreaming of a future, a future with a long and healthy life, not lived in the shadow of cancer but in the... full article
11th Annual TOP Conference – Don’t Forget Clinical Trials
Imaging Endpoints CMO and Founder, Ronald Korn, MD., Ph.D. presents “New Imaging Techniques to Aid Creative Clinical Trial Designs.” ... full article